Shattuck Labs, Inc. (STTK)
2.97
+0.37
(+14.23%)
USD |
NASDAQ |
Dec 04, 16:00
2.93
-0.04
(-1.35%)
After-Hours: 06:10
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 187.94M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 137.6% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 167.06 |
| Price to Book Value | 2.016 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0282 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.73% |
Profile
| Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX. |
| URL | http://www.shattucklabs.com |
| Investor Relations URL | https://ir.shattucklabs.com/ |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Shattuck Labs, Inc. is a biotechnology company, which engages in the research and development of potential treatments for inflammatory and immune-mediated diseases. It focuses on developing a potential first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX. |
| URL | http://www.shattucklabs.com |
| Investor Relations URL | https://ir.shattucklabs.com/ |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |